NASDAQ · GRTS
Healthcare · Biotechnology
$0.03
Down-$0.02 (-31.78%)
Updated Sep 30, 2026, 9:22 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · GRTS
1M range · 0 trading sessions · Daily adjusted prices
GRTS does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning GRTS.
Company
Market Activity
Research & News
GRTS research
Company profile and research snapshot.
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 2, 2024 | B. Riley Securities | Neutral | — |
| Oct 2, 2024 | Jones Trading | Hold | — |
| Oct 1, 2024 | HC Wainwright & Co. | Neutral | — |
| Oct 1, 2024 | JMP Securities | Market Perform | — |
| Aug 15, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Aug 8, 2024
Gritstone bio, Inc. is facing a class action lawsuit alleging that the company made false and misleading statements about the timeline and funding for its COVID-19 vaccine trial, leading to a workforce reduction and stock price decline.
GlobeNewswire Inc. · Aug 4, 2024
Gritstone bio, Inc. (NASDAQ: GRTS) is facing a securities class action lawsuit due to alleged false and/or misleading statements about its ability to launch a COVID-19 vaccine study and maintain its financial position. Investors who purchased Gritstone securities between March 9, 2023 and February 29, 2024 are encouraged to join the lawsuit by the August 6, 2024 deadline.
GlobeNewswire Inc. · Jul 25, 2024
Gritstone bio, Inc. (NASDAQ: GRTS) investors are encouraged to seek legal counsel before the August 6, 2024 deadline in a securities class action lawsuit. The lawsuit alleges that the company made false and/or misleading statements regarding its ability to launch a COVID-19 vaccine study, which negatively impacted its financial position.
GlobeNewswire Inc. · Jul 19, 2024
A securities class action lawsuit has been filed against Gritstone bio, Inc. (NASDAQ: GRTS) for allegedly making false and/or misleading statements about its ability to launch a COVID-19 vaccine study, which impacted its financial position.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GRTS.
No results
No recent SID articles mention GRTS.
